LTR Pharma Secures Definitive US Deal with Shed to Launch ROXUS Intranasal ED Treatment
LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.